{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Aytu BioPharma, Inc. "},"Symbol":{"label":"Symbol","value":"AYTU"},"Address":{"label":"Address","value":"373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD, Colorado, 80112, United States"},"Phone":{"label":"Phone","value":"+1 720 437-6580"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments BioPharma and Consumer Health segments of which it generates maximum revenue from the BioPharma segment."},"CompanyUrl":{"label":"Company Url","value":"https://www.aytubio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Christopher Brooke","title":"Chief Operating Officer"},{"name":"Joshua R. Disbrow","title":"Chairman &amp; Chief Executive Officer"},{"name":"Russell Lee McMahen","title":"Senior Vice President-Research &amp; Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}